The pharmacogenetics of analgesia: toward a genetically-based approach to pain management
- 1 August 2001
- journal article
- review article
- Published by Taylor & Francis in Pharmacogenomics
- Vol. 2 (3) , 177-194
- https://doi.org/10.1517/14622416.2.3.177
Abstract
Interindividual differences in the experience of pain have been appreciated clinically for over a century. More recently, there has been a growing body of evidence demonstrating differences in analgesic response to various pharmacotherapies, although the source of this variability largely remains to be explained. To this end, basic science research is beginning to identify the allelic variants that underlie such antinociceptive variability using a multiplicity of animal models, and powerful genetic approaches are being exploited to accelerate this process. Although the vast majority of these studies have focused on the pharmacogenetics of opioids, owing to their prominent status as analgesics, the number of pharmacotherapies evincing genetically-based variability is rapidly expanding. In addition, analogous studies have been undertaken in humans, as a small but growing number of clinical trials have begun to evaluate prospectively the existence, if oftentimes not the origin, of interindividual differences in analgesic drug response. Importantly, with a few notable exceptions, such efforts have primarily identified differences in analgesic efficacy and/or potency between male and female human subjects. Looking toward the future development of one or more widely utilised, pharmacogenetic screens that would lead to modifications in treatment planning, at least with respect to the pharmacologic management of pain, this review will document the breadth of genetically-based variability in drug-mediated antinociception in animals. Specific examples in which the gene or genes underlying such variability have been postulated or identified will be given, while highlighting the effect of sex and its interactions with other genetic backgrounds. Finally, we will summarise and evaluate the literature on pharmacogenetic differences in human analgesic drug response, for which the influence of sex has served as one of the better studied and heuristically insightful examples.Keywords
This publication has 90 references indexed in Scilit:
- Bioactivation of the narcotic drug codeine in human liver is mediated by the polymorphic monooxygenase catalyzing debrisoquine 4-hydroxylation (cytochrome P-450 dbl/bufI)Published by Elsevier ,2005
- Influence of inheritance and fostering on sensitivity to effects of morphine on nociception and locomotor activity in two inbred rat strainsNeuropharmacology, 1996
- The genetic polymorphism of debrisoquine/sparteine metabolism — Clinical aspectsPharmacology & Therapeutics, 1990
- Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental painPain, 1990
- POLYMORPHIC O-DEMETHYLATION OF CODEINEThe Lancet, 1988
- Opioids and behavior: genetic aspectsCellular and Molecular Life Sciences, 1988
- C57BL/6J-bg J (beige) mice: Differential sensitivity in the tail flick test to centrally administered MU- and delta-opioid receptor agonistsLife Sciences, 1987
- An Appraisal of Codeine as an Analgesic: Single‐Dose AnalysisThe Journal of Clinical Pharmacology, 1984
- Analgesic responses to morphine and placebo in individuals with postoperative painPain, 1981
- Opiate receptors in mice: Genetic differencesLife Sciences, 1975